EQT Life Sciences

Christoph Broja is a Partner at EQT Life Sciences with investment experience across healthcare and life sciences sectors. He has participated in approximately 10 growth equity and venture investments in biotech, pharma, molecular diagnostics, and healthcare services, and has been involved in deal origination, due diligence, valuation, portfolio management, and exit planning across funds deploying approximately $2 billion. He holds the CFA charter.

Philip Scheltens is Partner and Head of the Dementia Fund at EQT Life Sciences, having joined as a Partner at LSP in 2021 before LSP merged with EQT. Before that, he served as Director of the Alzheimer Center at Amsterdam University Medical Center. He is an MD in neurology with a PhD in Medicine from VU University Amsterdam and is Professor of Neurology at Amsterdam University Medical Center.

Originated the idea for the EQT Dementia Fund and, with Philip Scheltens, designed its scope and raised investor commitments. Leads EQT Life Sciences.

Fouad Azzam is a Partner at EQT Life Sciences focused on multi-stage venture capital investment in biotechnology and medical technology companies. He brings operating experience and board-level expertise across public and private companies, with service on audit, compensation, and transaction committees. His background spans corporate strategy, capital allocation, mergers and acquisitions, and governance in healthcare, medical devices, biotechnology, and pharmaceuticals.

Mark Wegter keeps a low public profile, preferring behind-the-scenes, governance-heavy, board-focused investing rooted in deep experience as a director and a background in traditional European private equity and growth capital.

René Kuijten leads EQT Life Sciences and has been a Partner at EQT since 2022; he previously served as Managing Partner at LSP from 2001 until it merged with EQT and was renamed EQT Life Sciences. Before LSP, he spent eight years as a senior consultant at McKinsey & Company, where he co-led the European Healthcare Practice. He holds an MD from Utrecht University, a PhD from the University of Amsterdam based on research as a WHO fellow at the University of Pennsylvania, and an MBA from INSEAD.

Head of the Health Economic Funds at EQT Life Sciences and Partner at EQT since 2022; previously a Partner at LSP (2012-2022, which became EQT Life Sciences), Managing Director at VIB in Belgium leading business development, and senior advisor at IWT. Holds a PhD in biotechnology from the University of Ghent.

Bruno Holthof is a Partner at EQT Life Sciences and Visiting Professor of Health Innovation at the University of Oxford. He previously served as Chief Executive Officer of Oxford University Hospitals from 2015 to 2022 and as CEO of the Antwerp Hospital Network from 2004 to 2015. He holds an MBA from Harvard Business School and an MD/PhD from the University of Leuven, and currently serves as a non-executive director at BUPA and chair of the boards of Tristel and Financière de Tubize.

Vincent Brichard is a Venture Partner at EQT Group, a European venture capital firm focused on biotechnology. With over a decade of professional experience, he specializes in clinical trials, oncology, and research and development strategy, supporting portfolio companies in clinical development and strategic initiatives.

Ishaan Tewarie is a Vice President at EQT Group's Life Sciences business line, focusing on healthcare and life sciences investments. He brings experience in investing, company building, and board-level engagement with biotech and medtech companies, supported by an MD and research fellowship at Harvard Medical School. His background includes investment training and think tank participation.

Philipp Bräuer is a Vice President at EQT Life Sciences with a background in structural biology. He focuses on healthcare and life science investment opportunities.

Arno de Wilde is a Managing Director at EQT Life Sciences and co-founder of its neuroscience fund, which manages €273 million in assets. He holds an MD and PhD in neurology from Amsterdam UMC, where he completed six years of clinical practice, and earned an MBA from INSEAD. De Wilde serves as a director on the boards of Aerska, Atalanta Therapeutics, and VectorY Therapeutics, and has published over 20 manuscripts and a book chapter on clinical trial design.

Madeleine Magnerius is a Director at EQT Group. Her investment focus includes businesses in health preservation and longevity, with particular interest in women's health, as well as scalable, non-discretionary ventures. She also serves as a seed and angel investor supporting select entrepreneurs.

Sonia Hallen is an Investment Manager at Gilde Healthcare with a PhD and background in life sciences investing and entrepreneurship. She has published research in regenerative medicine and holds experience in strategy and business development across the healthcare sector, ranging from early-stage HealthTech companies to large pharmaceutical firms.